Blinatumomab
Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
Novartis Pharmaceuticalsmonoclonal_antibodyPhase 3Active
BB
67/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 60/ 100
- Competitive Position
- 81/ 100
Competitive context
9 Active assets in the Leukemia, Lymphoblastic, Acute, Philadelphia-Positive cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cytosin-Arabinosid Novartis Pharmaceuticals | Phase 3 | BB |
DEXAMETHASONE Novartis Pharmaceuticals | Phase 3 | BB |
Dasatinib SWOG Cancer Research Network | Phase 3 | BB |
Olverembatinib Institute of Hematology & Blood Diseases Hospital, China | Phase 3 | BB |
(+)-VINCRISTINE Novartis Pharmaceuticals | Phase 3 | B |
View all 13 →
Same molecule, other indications
Blinatumomab is also rated in:
B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)Dormant
BBB
Indicative ·
72 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →